175 related articles for article (PubMed ID: 34244607)
21. hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma.
Cocco E; Hu Z; Richter CE; Bellone S; Casagrande F; Bellone M; Todeschini P; Krikun G; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Buza N; Pecorelli S; Lockwood CJ; Santin AD
Br J Cancer; 2010 Sep; 103(6):812-9. PubMed ID: 20700124
[TBL] [Abstract][Full Text] [Related]
22. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma.
El-Sahwi K; Bellone S; Cocco E; Cargnelutti M; Casagrande F; Bellone M; Abu-Khalaf M; Buza N; Tavassoli FA; Hui P; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Br J Cancer; 2010 Jan; 102(1):134-43. PubMed ID: 19920829
[TBL] [Abstract][Full Text] [Related]
23. Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro.
Paik D; Cocco E; Bellone S; Casagrande F; Bellone M; Siegel EE; Richter CE; Schwartz PE; Rutherford TJ; Santin AD
Gynecol Oncol; 2010 Oct; 119(1):140-5. PubMed ID: 20673976
[TBL] [Abstract][Full Text] [Related]
24. Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody.
Varughese J; Cocco E; Bellone S; de Leon M; Bellone M; Todeschini P; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Cancer; 2011 Jul; 117(14):3163-72. PubMed ID: 21246534
[TBL] [Abstract][Full Text] [Related]
25. Proteomic analysis reveals a role for PAX8 in peritoneal colonization of high grade serous ovarian cancer that can be targeted with micelle encapsulated thiostrepton.
Hardy LR; Pergande MR; Esparza K; Heath KN; Önyüksel H; Cologna SM; Burdette JE
Oncogene; 2019 Aug; 38(32):6003-6016. PubMed ID: 31296958
[TBL] [Abstract][Full Text] [Related]
26. Pax8: a marker for carcinoma of Müllerian origin in serous effusions.
Tong GX; Devaraj K; Hamele-Bena D; Yu WM; Turk A; Chen X; Wright JD; Greenebaum E
Diagn Cytopathol; 2011 Aug; 39(8):567-74. PubMed ID: 20607683
[TBL] [Abstract][Full Text] [Related]
27. PAX8 expression in uterine adenocarcinomas and mesonephric proliferations.
Yemelyanova A; Gown AM; Wu LS; Holmes BJ; Ronnett BM; Vang R
Int J Gynecol Pathol; 2014 Sep; 33(5):492-9. PubMed ID: 25083965
[TBL] [Abstract][Full Text] [Related]
28. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
[TBL] [Abstract][Full Text] [Related]
29. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma.
Laury AR; Hornick JL; Perets R; Krane JF; Corson J; Drapkin R; Hirsch MS
Am J Surg Pathol; 2010 May; 34(5):627-35. PubMed ID: 20414098
[TBL] [Abstract][Full Text] [Related]
30. Claudin-3 and claudin-4 expression in serous papillary, clear-cell, and endometrioid endometrial cancer.
Konecny GE; Agarwal R; Keeney GA; Winterhoff B; Jones MB; Mariani A; Riehle D; Neuper C; Dowdy SC; Wang HJ; Morin PJ; Podratz KC
Gynecol Oncol; 2008 May; 109(2):263-9. PubMed ID: 18313739
[TBL] [Abstract][Full Text] [Related]
31. High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma.
Biron-Shental T; Drucker L; Altaras M; Bernheim J; Fishman A
Eur J Surg Oncol; 2006 Dec; 32(10):1097-100. PubMed ID: 16650962
[TBL] [Abstract][Full Text] [Related]
32. [Origin of ovarian epithelial inclusions and its relationship with the development of low-grade serous carcinoma].
Xiang L; Li J; Wang LJ; Zheng WX; Kong BH
Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):729-35. PubMed ID: 22321344
[TBL] [Abstract][Full Text] [Related]
33. BRCA2 germline mutation in a woman with uterine serous papillary carcinoma--case report.
Lavie O; Ben-Arie A; Pilip A; Rennert G; Cohen Y; Feiner B; Auslnader R
Gynecol Oncol; 2005 Nov; 99(2):486-8. PubMed ID: 16051327
[TBL] [Abstract][Full Text] [Related]
34. Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer.
Santin AD; Bellone S; Siegel ER; Palmieri M; Thomas M; Cannon MJ; Kay HH; Roman JJ; Burnett A; Pecorelli S
Am J Obstet Gynecol; 2005 Mar; 192(3):813-8. PubMed ID: 15746676
[TBL] [Abstract][Full Text] [Related]
35. Utility of paired box gene 8 (PAX8) expression in fluid and fine-needle aspiration cytology: an immunohistochemical study of metastatic ovarian serous carcinoma.
McKnight R; Cohen C; Siddiqui MT
Cancer Cytopathol; 2010 Oct; 118(5):298-302. PubMed ID: 20572292
[TBL] [Abstract][Full Text] [Related]
36. Insulin-like growth factor-I receptor inhibition by specific tyrosine kinase inhibitor NVP-AEW541 in endometrioid and serous papillary endometrial cancer cell lines.
Attias-Geva Z; Bentov I; Fishman A; Werner H; Bruchim I
Gynecol Oncol; 2011 May; 121(2):383-9. PubMed ID: 21295335
[TBL] [Abstract][Full Text] [Related]
37. Papillary serous carcinoma of the peritoneum coexisting with or after endometrial carcinoma.
Altaras MM; Bernheim J; Zehavi T; Drucker L; Uziel O; Fishman A
Gynecol Oncol; 2002 Feb; 84(2):245-51. PubMed ID: 11812082
[TBL] [Abstract][Full Text] [Related]
38. Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners.
Sarfstein R; Friedman Y; Attias-Geva Z; Fishman A; Bruchim I; Werner H
PLoS One; 2013; 8(4):e61537. PubMed ID: 23620761
[TBL] [Abstract][Full Text] [Related]
39. Loss of PAX8 in high-grade serous ovarian cancer reduces cell survival despite unique modes of action in the fallopian tube and ovarian surface epithelium.
Rodgers LH; Ó hAinmhire E; Young AN; Burdette JE
Oncotarget; 2016 May; 7(22):32785-95. PubMed ID: 27129161
[TBL] [Abstract][Full Text] [Related]
40. The mechanism of action of the histone deacetylase inhibitor vorinostat involves interaction with the insulin-like growth factor signaling pathway.
Sarfstein R; Bruchim I; Fishman A; Werner H
PLoS One; 2011; 6(9):e24468. PubMed ID: 21931726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
